Pepticrad: Oncolytic Immunotherapy Approach for Solid Tumors In Combination With Checkpoint Blockade

Time: 3:30 pm
day: Day Two


  • PeptiCRAd is a rapidly adaptable and cost-effective therapeutic cancer vaccine platform targeting multiple tumor antigens simultaneously
  • Systemic T-cell mediated antitumor efficacy is synergistic with checkpoint blockade therapy
  • First-in-human Phase 1 clinical trial starting H2/2022.